X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SBCH: Blockbuster June quarter - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 25, 2003

    SBCH: Blockbuster June quarter

    GlaxoSmithkline Consumer Healthcare (SBCH) has posted a strong 27% topline growth during the June quarter. It seems that the company's relaunch strategy for both Horlicks and Boost seems to have rubbed off on the performance. It may also be an indication that the inventory correction undertaken by the company last year is now over. There is a minor difference between our revenue growth and the reported growth due to change in numbers of previous quarter figures.

    (Rs m) 2QFY03 2QFY04 Change 1HFY03 1HFY04 Change
    Net Sales 1,561 1,976 26.6% 3,416 3,793 11.0%
    Other Income 39 63 60.4% 80 102 27.4%
    Expenditure 1,265 1,595 26.1% 2,660 3,062 15.1%
    Operating Profit (EBDIT) 296 381 28.8% 756 731 -3.3%
    Operating Profit Margin (%) 19.0% 19.3%   22.1% 19.3%  
    Interest (8) 4 - (5) 7 -
    Depreciation 34 91 169.3% 68 182 169.0%
    Profit before Tax 310 349 12.6% 773 644 -16.7%
    Tax 88 123 40.0% 257 222 -13.7%
    Extraordinary items 0 -3 - 0 -18 -
    Profit after Tax/(Loss) 222 223 0.5% 516 405 -21.6%
    Net profit margin (%) 14.2% 11.3%   15.1% 10.7%  
    No. of Shares 45.4 45.4   45.4 45.4  
    Diluted Earnings per share* 19.6 19.6   22.8 17.8  
    P/E Ratio   13.5     14.9  
    *(annualised)            

    One must remember that the June quarter last year was exceptionally bad for the company. Topline during that period had declined by a huge 26%. If we see from this angle, then the company has only managed to recoup lost ground. But one thing is for sure. The result posted by SBCH this quarter are likely to pep up investor interest towards this malted beverage major once again.

    2002 was one of the worst years for the company, wherein it reported a 12.5% dip in topline and nearly 33% decline in profits. Even in the March quarter this year, GSK Consumer had reported a marginal dip in the topline. The strong growth witnessed this quarter is a sign that the company has managed to address topline concerns successfully. This could have been led by new product introductions in an effort to reposition its ageing brands.

    Expenses as a % of sales
    Particulars 2QFY03 2QFY04 1HFY03 1HFY04
    Stock -6.1% -9.3% -3.4% -3.5%
    RM 36.3% 41.7% 34.7% 36.8%
    Finished goods 1.3% 1.0% 0.9% 0.9%
    Staff cost 13.2% 10.6% 11.7% 10.8%
    Advt. 11.8% 9.0% 10.3% 9.7%
    Other exps 22.0% 25.8% 21.8% 24.0%
    Patent and trademark 1.6% 1.2% 1.1% 1.3%
    Def. Rev. exps. 0.8% 0.6% 0.7% 0.7%
    Total 81.0% 80.7% 77.9% 80.7%

    At the operating level, expenses grew almost neck to neck with the topline. Consequently, GSK Consumer did not see significant benefits on the operating margins front. Higher raw material and other expense were the key contributors to the expense growth. Depreciation provisioning also increased on account of the new 26,000 tonne malted food plant at Sonepat. All this resulted in the company declaring almost similar net profits as in the corresponding quarter last year. On a consolidated half year basis, SBCH has clocked an encouraging 11% topline growth, but a 22% bottomline dip. The company has declared an interim dividend of Rs 3.3 per share.

    At Rs 266, the stock trades at 15x annualised 1HFY04 earnings with market cap to sales at 1.6x. As said earlier, the strong growth in June quarter topline is likely to perk investor interest towards the stock. We are still awaiting the management's take on the topline growth and whether it is a sustainable trend. But overall, we are enthused by prospects of a turnaround story.

     

     

    Equitymaster requests your view! Post a comment on "SBCH: Blockbuster June quarter". Click here!

      
     

    More Views on News

    GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)

    Jun 20, 2017

    While GSK consumer reported muted revenue growth, volumes are seen to be recovering.

    GSK Consumer: Price Hike Hurts Volumes (Quarterly Results Update - Detailed)

    Nov 30, 2016

    GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.

    GSK Consumer: Slowdown in demand impacts sales (Quarterly Results Update - Detailed)

    Oct 5, 2016

    GSK Consumer Healthcare has announced the first quarter results of the financial year 2016-2017 (1QFY17). The company's sales declined by 1.4% YoY while net profit rose by 2.9% YoY during the quarter.

    GSK Consumer: A Forgetful Year (Quarterly Results Update - Detailed)

    Jun 1, 2016

    GSK Consumer Healthcare announced its results for the quarter and year ended March 2016. During the quarter, sales and profit came in lower by 9% YoY and 8% YoY respectively.

    GSK Consumer: Feeling the Growth Pressures? (Quarterly Results Update - Detailed)

    Feb 15, 2016

    GSK Consumer Healthcare announced its results for the quarter ended December 2015. While revenues were up by 2% YoY, profits were higher by 37% YoY.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK CONSUMER SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK GSK CONSUMER

    • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK CONSUMER - NESTLE COMPARISON

    Compare Company With Charts

    COMPARE GSK CONSUMER WITH

    MARKET STATS